Variation in timing of respiratory syncytial virus outbreaks: Lessons from national surveillance

Pediatric Infectious Disease Journal

Volumn 26, Issue 11 SUPPL., 2007, Pages

  Panozzo, Catherine A ^a   Fowlkes, Ashley L ^a   Anderson, Larry J ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Antigen detection; Immune prophylaxis; National Respiratory and Enteric Virus Surveillance System; Palivizumab; RSV seasonality

Indexed keywords

ANTIGEN;

ANTIGEN DETECTION; CALCULATION; COMMUNITY; COMPARATIVE STUDY; CONFERENCE PAPER; ENTERIC VIRUS; EPIDEMIC; HUMAN; LABORATORY; MEASUREMENT; METHODOLOGY; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEASON; SEASONAL VARIATION; UNITED STATES; VIRUS INFECTION; WINTER;

EID: 37349116291     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e318157da82     Document Type: Conference Paper

References (13)

1. Steiner RW. Treating acute bronchiolitis associated with RSV. Am Fam Physician. 2004;69:325-330.
2. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J. 2003;22(2 suppl):S21-S32.
3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1995. JAMA. 1999;282:1440-1447.
4. Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care. 2003;48:209-231.
5. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143(5 suppl):S112-S117.
6. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 pt 1):1447-1452.
7. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-1216.
8. Schrand LM, Elliott JM, Ross MA, Bell EF, Mutnick AH. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother. 2001;35:1186-1193.
9. Gilchrist S, Török TJ, Gary HE, Alexander JP, Anderson LJ. National surveillance for respiratory syncytial virus, United States, 1985-1990. J Infect Dis. 1994;170:986-990.
10. Mullins JA, Lamonte AC, Breese JS, Anderson LJ. Substantial variability in community RSV season timing: an analysis using the National Respiratory and Enteric Viruses Surveillance System (NREVSS). Pediatr Infect Dis J. 2003;22:857-862.
11. Brief report: respiratory syncytial virus activity-United States, 2005-2006. MMWR Morbid Mortal Wkly Rep. 2006;55:1277-1279.
12. Peret TCT, Hall CB, Hammond GW, et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in five communities in North America. J Infect Dis. 2000;181:1891-1896.
13. Peret TCT, Hall CB, Schnabel KC, Golub JA, Anderson LJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol. 1998;79:2221-2229.